Insulin Makers Can't Nix 340B Antitrust Claims On Remand
A New York federal judge trimmed proposed class action claims by providers alleging Sanofi-Aventis and other drugmakers colluded to deny them discounts on insulin products under the 340B program, allowing most...To view the full article, register now.
Already a subscriber? Click here to view full article